Vertex Announces FDA Fast Track, Phase 1/2 Start for Cell Therapy for Type 1 Diabetes

– VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes –

– VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation –

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the company has initiated a clinical trial for VX-880 in patients who have type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness.

https://finance.yahoo.com/news/vertex-announces-fda-fast-track-125500071.html